

CLAIMS

1. A method of selecting a sample comprising T cells for adoptive immunotherapy, the method comprising determining the expression of granzyme B by lymphocytes in the sample and selecting the sample for adoptive immunotherapy if at least 5% of the lymphocytes in the sample express granzyme B.
2. A method of selecting a sample comprising T cells for inclusion in a cell bank, the method comprising determining the expression of granzyme B by lymphocytes in the sample and selecting the sample for inclusion in a cell bank if at least 5% of the lymphocytes in the sample express granzyme B.
3. A method of selecting for adoptive immunotherapy a sample comprising T cells from a library of samples, the method comprising screening the library of samples for the expression of granzyme B by lymphocytes in the samples and selecting a sample from the library of samples for adoptive immunotherapy in which at least 5% of the lymphocytes in the sample express granzyme B.
4. A method of selecting for inclusion in a cell bank samples comprising T cells from a library of samples, the method comprising screening the library of samples for the expression of granzyme B by lymphocytes in the samples and selecting samples for inclusion in a cell bank in which at least 5% of the lymphocytes in the sample express granzyme B.
5. A method of selecting a sample comprising T cells for *ex vivo* expansion, comprising:
 - (a) inducing proliferation in T cells from a portion of the sample,
 - (b) determining the expression of granzyme B by the lymphocytes in the portion of the sample; and
 - (c) selecting the sample for expansion if at least 5% of the lymphocytes in the sample express granzyme B.

6. The method of claim 5, further comprising selecting the sample for inclusion into a cell bank.
7. The method of claim 5, further comprising selecting the sample for adoptive immunotherapy.
8. The method of any one of claims 1 to 7, wherein the sample is selected if at least 10% of the lymphocytes in the sample express granzyme B.
9. The method of any one of claims 1 to 7, wherein the sample is selected if at least 15% of the lymphocytes in the sample express granzyme B.
10. The method of any one of claims 1 to 7, wherein the sample is selected if at least 20% of the lymphocytes in the sample express granzyme B.
11. The method of any one of the preceding claims, wherein the expression of granzyme B is determined by Fluorescence Activated Cell Sorting (FACS) or ELISpot.
12. The method of any one of claims 1 to 11, wherein the T cells are incubated with antigen-presenting cells to induce proliferation of the T cells before the expression of granzyme B by the lymphocytes is determined.
13. The method of any one of claims 1 to 12, further comprising determining the expression of CD8 by cells in the sample and selecting the sample if at least 20% of the cells express CD8.
14. The method of claim 13, wherein the sample is selected if at least 25% of the cells express CD8.
15. The method of claim 13, wherein the sample is selected if at least 30% of the cells express CD8.

16. The method of any one of claims 1 to 15, further comprising determining the expression of CD4 by cells in the sample and selecting the sample if at least 10% of the cells express CD4.
17. The method of claim 16, wherein the sample is selected if at least 15% of the cells in the sample express CD4.
18. The method of claim 16, wherein the sample is selected if at least 25% of the cells in the sample express CD4.
19. The method of any one of claims 1 to 18, wherein the selected T cells are stored in a cell bank after selection.
20. The method of any one of claims 1 to 19, wherein the T cells express a TCR specific for an Epstein-Barr Virus (EBV) peptide presented on a class I MHC.
21. The method of claim 20, wherein the EBV peptide comprises any one of a LMP1 peptide, a LMP2A peptide, an EBNA1 peptide, or fragments thereof.
22. Use of a composition comprising the T cells of any one of claims 1 to 21 in the manufacture of a medicament for the treatment of cancer in a subject.
23. The use of claim 22, wherein the cancer is an Epstein-Barr Virus-associated cancer.
24. The use of claim 22 or 23, wherein the subject has nasopharyngeal carcinoma, NK/T cell lymphoma, Epstein-Barr Virus-associated gastric carcinoma, or Epstein-Barr Virus-associated leiomyosarcoma.
25. Use of a composition comprising the T cells of any one of claims 1 to 21 in the manufacture of a medicament for the treatment of post-transplant lymphoproliferative disorder in a subject.

26. Use of a composition comprising the T cells of any one of claims 1 to 21 in the manufacture of a medicament for the treatment of an autoimmune disorder in a subject.
27. The use of claim 26, wherein the autoimmune disorder is multiple sclerosis.
28. The use of any one of claims 22 to 27, wherein the T cells are allogeneic to the subject.
29. The use of any one of claims 22 to 28, wherein the T cells are obtained from a cell bank.
30. The use of any one of claims 22 to 27, wherein the T cells are autologous to the subject.
31. A cell bank of samples comprising T cells, wherein the cell bank is enriched for samples in which at least a threshold level of lymphocytes in the sample express granzyme B, wherein the threshold level of lymphocytes expressing granzyme B is at least 5%.
32. The cell bank of claim 31, wherein at least 25% of the samples in the cell bank have at least the threshold level of lymphocytes in the sample expressing granzyme B.
33. The cell bank of claim 31, wherein at least 50% of the samples in the cell bank have at least the threshold level of lymphocytes in the sample expressing granzyme B.
34. The cell bank of claim 31, wherein at least 75% of the samples in the cell bank have at least the threshold level of lymphocytes in the sample expressing granzyme B.
35. The cell bank of claim 31, wherein 100% of the samples in the cell bank have at least the threshold level of lymphocytes in the sample expressing granzyme B.
36. The method of any one of claims 1 to 21, wherein the T cells are CD8⁺ T cells.
37. The method of claim 36, wherein the CD8⁺ T cells are cytotoxic T lymphocytes (CTLs).

38. The method of claim 37, wherein the CTLs express IFN γ , TNF, IL-2 and CD107.
39. The method of any one of claims 1 to 21, wherein the T cells are CD4⁺ T cells.
40. The cell bank of any one of claims 31 to 35, wherein the T cells are CD8⁺ T cells.
41. The cell bank of claim 40, wherein the CD8⁺ T cells are cytotoxic T lymphocytes (CTLs).
42. The cell bank of any one of claims 31 to 35, wherein the T cells are CD4⁺ T cells.